Shukra Pharmaceuticals sets Sep 21, 2026 as Record Date for Final Dividend of ₹0.01
Shukra Pharmaceuticals has set September 21, 2026, as the Record Date for its Final Dividend. Shareholders are eligible for ₹0.01 per equity share for FY 2025-26, subject to approval at the AGM on September 28, 2026.
The dividend amount is very small (₹0.01 per share), indicating a minimal financial impact on shareholders and the company's valuation. The announcement is primarily a procedural update.
The announcement is a routine regulatory filing regarding the record date for a final dividend, which is a standard corporate action. The dividend amount is nominal.
Shukra Pharmaceuticals Limited has announced that Monday, September 21, 2026, has been fixed as the Record Date to determine the eligibility of shareholders for the Final Dividend. This dividend amounts to ₹0.01 per equity share of face value ₹1 each for the financial year ended March 31, 2026.
The Final Dividend is subject to the declaration by the company's members at the upcoming 33rd Annual General Meeting (AGM), which is scheduled to be held on Monday, September 28, 2026.
If declared at the AGM, the Final Dividend will be paid to the shareholders whose names appear in the company's Register of Members or in the records of the Depositories as of the Record Date, September 21, 2026. The payment will be made within days from the date of declaration, as per the Companies Act, 2013.
What to do with a filing like this
Shukra Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shukra Pharmaceuticals Limited. Read the original for the full detail.